BioMarin Pharmaceutical Inc. (BMV:BMRN)

Market Cap	190.32B
Revenue (ttm)	56.75B
Net Income (ttm)	9.55B
Shares Out	n/a
EPS (ttm)	49.17
PE Ratio	19.94
Forward PE	12.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Average Volume	114
Open	980.00
Previous Close	n/a
Day's Range	980.00 - 980.00
52-Week Range	980.00 - 1,480.00
Beta	n/a
RSI	32.38
Earnings Date	Feb 20, 2026

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BMRN

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD